论文部分内容阅读
目的:观察爱普列特治疗Ⅱ型糖尿病患者BPH的临床疗效与安全性。方法:选择合并BPH的Ⅱ型糖尿病患者60例,口服爱普列特片5 mg,每天2次,疗程4个月:同时按中国糖尿病防治指南进行规则的降糖治疗。采用国际前列腺症状评分(IPSS)、生活质量评分(QOL)、剩余尿量(Ru)、最大尿流率(Q_(max))、前列腺体积(PV)和前列腺特异抗原(PSA)等指标评价其临床疗效。结果:与治疗前比较,治疗4个月后入选患者的IPSS、QOL、Ru、Q_(max)、PV和PSA均得到显著改善(P<0.05),总有效率为86.7%。治疗过程中,患者的血糖水平控制良好,未观察到明显的不良反应。结论:爱普列特治疗Ⅱ型糖尿病患者BPH具有较好的疗效与安全性。
Objective: To observe the clinical efficacy and safety of epristeride in the treatment of type 2 diabetes mellitus (BPH). Methods: Sixty patients with type Ⅱ diabetes mellitus complicated with BPH were selected and treated with 5 mg of epristeride tablets twice a day for 4 months. At the same time, regular glycemic control was conducted according to Chinese guidelines for the prevention and treatment of diabetes. The indexes of IPSS, QOL, Ru, Qmax, prostate volume and prostate specific antigen (PSA) were evaluated Clinical efficacy. Results: Compared with those before treatment, IPSS, QOL, Ru, Qmax, PV and PSA were significantly improved (P <0.05). The total effective rate was 86.7%. During treatment, the patient’s blood glucose level was well controlled and no apparent adverse reactions were observed. Conclusion: Epristeride in the treatment of type Ⅱ diabetes BPH has good efficacy and safety.